Cardiovascular Systems NASDAQ: CSII
Cardiovascular Systems, Inc., a medical technology company, develops, manufactures, and markets devices to treat vascular diseases
Name | Cardiovascular Systems |
Ticker | CSII |
Exchange | NASDAQ |
Sector | Health Care |
Industry | Medical Devices |
Price
52W Low/High |
41.30
27.86 / 47.19 |
Momentum | Weak Down |
Market cap | 1.7 B |
1Y Total Return |
9.78%
Below Average |
1Y Volatility |
52.08%
Less Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Cardiovascular Systems, Inc., a medical technology company, develops, manufactures, and markets devices to treat vascular diseases
Details
Ticker | CSII |
Name | Cardiovascular Systems |
ISIN | US1416191062 |
CUSIP | 141619106 |
Exchange | NASDAQ |
Sector | Health Care |
Industry | Medical Devices |
Country | USA |
Currency | U.S. Dollar |
Share as of 2/26/21
Close Price | 41.30 |
52W Low/High | 27.86 / 47.19 |
Market cap | 1.7 B |
1Y Total Return |
9.78%
Below Average |
1Y Volatility |
52.08%
Less Risk |
Beta | 2.93 |
PE (trailing) | - |
12M Dividends | - |
Last Dividend Date | - |
Dividend Yield | - |
Fin. Strength
Net Profit Margin | -8.8% |
Cash from Op. / Cur. Liabilities | -0.24 |
Diluted Earnings / Share | -0.57 |
ROE | - |
ROIC | -11.3% |
Price / Revenue | 7.0 |
Price / Book | 5.9 |
Price / CF | -140.0 |
Current Ratio | 6.1 |
Cur.Liabilities / Tot.Liabilities | 0.6 |
Financial Leverage | 0.08 |
in Mils USD |
rolling-year up to December
|
||||||
---|---|---|---|---|---|---|---|
Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Revenue |
228
|
264
|
231
|
207
|
193
|
181
|
|
Gross Profit |
180
|
212
|
188
|
168
|
156
|
143
|
|
R&D |
40
|
40
|
28
|
24
|
23
|
30
|
|
EBITDA |
-14
|
-1
|
7
|
2
|
-24
|
-44
|
|
Operating Income |
-19
|
-8
|
2
|
-3
|
-28
|
-48
|
|
Net Income exc. Extra |
-
|
-
|
2
|
-
|
-
|
-
|
|
per Share | |||||||
Diluted avg Shares |
39
|
34
|
34
|
33
|
33
|
33
|
|
EPS exc. Extra |
-0.57
|
-0.21
|
0.04
|
-0.10
|
-0.87
|
-1.49
|
|
Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Total Assets |
349
|
224
|
207
|
190
|
159
|
151
|
|
Cash, Eq & Invt ShortTerm |
225
|
109
|
119
|
108
|
80
|
67
|
|
Total Current Assets |
293
|
170
|
171
|
156
|
123
|
113
|
|
Total Non-Current Assets |
56
|
55
|
36
|
34
|
36
|
38
|
|
Intangibles |
16
|
21
|
5
|
5
|
5
|
5
|
|
Total Liabilities |
75
|
81
|
69
|
66
|
47
|
30
|
|
Total Current Liabilities |
48
|
53
|
39
|
33
|
32
|
28
|
|
Long Term Debt |
27
|
28
|
30
|
33
|
14
|
2
|
|
Shareholder equity |
274
|
143
|
139
|
124
|
112
|
121
|
|
Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Cash from Operations |
-11
|
5
|
14
|
5
|
8
|
-29
|
|
Depreciation |
4
|
4
|
4
|
4
|
4
|
3
|
|
Cash from Investing |
-115
|
-56
|
-5
|
-3
|
-1
|
-13
|
|
Capex |
4
|
3
|
2
|
2
|
2
|
12
|
|
Cash from Financing |
135
|
-2
|
2
|
26
|
7
|
6
|
|
Stock Issued |
139
|
4
|
4
|
5
|
7
|
6
|
|
Debt (LT) Issued |
0
|
0
|
0
|
21
|
0
|
0
|
|
Free Cash Flow |
-25
|
-3
|
2
|
-5
|
-22
|
-67
|
|
Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Net Profit Margin |
-
|
-
|
0.7%
|
-
|
-
|
-
|
|
NCFO / Op.Income |
-
|
-
|
836.3%
|
-
|
-
|
-
|
|
Current Ratio |
6.1
|
3.2
|
4.4
|
4.7
|
3.8
|
4.0
|
|
Financial Leverage D/E |
0.08
|
0.15
|
0.15
|
0.17
|
0.00
|
0.00
|
|
Return on Capital Avg |
-11.3%
|
-5.8%
|
7.5%
|
-4.1%
|
-54.0%
|
-89.7%
|
|
Return on Shareholder Equity |
-
|
-
|
1.3%
|
-
|
-
|
-
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available